专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08008448B2 Cotinine neutralizing antibody 有权
标题翻译：不宁中和抗体
公开(公告)号：US08008448B2
公开(公告)日：2011-08-30
申请号：US12048636
申请日：2008-03-14
申请人： Sunyoung Park , Junho Chung , Dohoon Lee , Jae-Gahb Park
发明人： Sunyoung Park , Junho Chung , Dohoon Lee , Jae-Gahb Park
IPC分类号： C07K16/00 , C07K16/46
CPC分类号： C07K16/16 , C07K16/44 , C07K2317/24 , C07K2317/55
摘要： The present application discloses monoclonal antibody against cotinine and nicotine.
摘要翻译：本申请公开了针对可替宁和尼古丁的单克隆抗体。

2. 发明申请

US20140056926A1 COMPLEX IN WHICH ANTI-COTININE ANTIBODY IS BOUND TO CONJUGATE OF COTININE AND BINDING SUBSTANCE, AND USE THEREOF 有权
标题翻译：其中抗血清抗体的复合物是缀合的蛋白质和结合物质，以及它们的用途
公开(公告)号：US20140056926A1
公开(公告)日：2014-02-27
申请号：US14111133
申请日：2012-04-16
申请人： Junho Chung , Sunyoung Park , Do Been Hwang , Hwa Kyoung Lee
发明人： Junho Chung , Sunyoung Park , Do Been Hwang , Hwa Kyoung Lee
IPC分类号： A61K47/48 , A61K31/465 , G01N33/94
CPC分类号： A61K47/6803 , A61K31/465 , A61K47/545 , A61K47/6849 , A61K47/6891 , A61K2039/505 , B82Y5/00 , C07D401/04 , C07D401/14 , C07K16/18 , C07K16/2848 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2317/94 , G01N33/94
摘要： The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.
摘要翻译：本发明涉及一种其中抗可可宁抗体与结合物质和可替宁结合的结合物以及该复合物的用途的复合物。根据本发明的复合物可以用作体外生物测定方法中的分析工具，并且可以保留结合材料的特异性反应性和生物学功能，以及诱导补体介导的细胞毒性（CDC）的能力，和抗体依赖性细胞毒性（ADCC）和延长的体内半衰期，这是抗体的固有特征。

3. 发明授权

US09867886B2 Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof 有权
公开(公告)号：US09867886B2
公开(公告)日：2018-01-16
申请号：US14111133
申请日：2012-04-16
申请人： Junho Chung , Sunyoung Park , Do Been Hwang , Hwa Kyoung Lee
发明人： Junho Chung , Sunyoung Park , Do Been Hwang , Hwa Kyoung Lee
IPC分类号： C07K16/44 , G01N33/94 , B82Y5/00 , A61K47/48 , C07D401/04 , C07D401/14 , A61K31/465 , C07K16/28 , A61K39/00 , C07K16/18
CPC分类号： A61K47/6803 , A61K31/465 , A61K47/545 , A61K47/6849 , A61K47/6891 , A61K2039/505 , B82Y5/00 , C07D401/04 , C07D401/14 , C07K16/18 , C07K16/2848 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2317/94 , G01N33/94
摘要： The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.

4. 发明授权

US06710165B2 IgE-dependent histamine-releasing factor-binding peptides 有权
标题翻译： IgE依赖性组胺释放因子结合肽
公开(公告)号：US06710165B2
公开(公告)日：2004-03-23
申请号：US09870472
申请日：2001-06-01
申请人： Kyunglim Lee , Junho Chung , Wha Jung Kim , Miyoung Kim , Jaehoon Jung
发明人： Kyunglim Lee , Junho Chung , Wha Jung Kim , Miyoung Kim , Jaehoon Jung
IPC分类号： A61K3800
CPC分类号： C07K14/705 , A61K38/00 , A61K38/03 , G01N33/5008 , Y02A50/411
摘要： Disclosed are IgE-dependent histamine-releasing factor (HRF) receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof in the medicinal area.
摘要翻译：公开了IgE依赖性组胺释放因子（HRF）受体，HRF结合肽和编码它们的核酸及其在药物区域中的用途。

5. 发明授权

US07655417B2 VCAM-1 specific monoclonal antibody 失效
标题翻译： VCAM-1特异性单克隆抗体
公开(公告)号：US07655417B2
公开(公告)日：2010-02-02
申请号：US11756437
申请日：2007-05-31
申请人： Junho Chung , Ji Eun Lee , Eun Kyung Ryu , Sukmook Lee
发明人： Junho Chung , Ji Eun Lee , Eun Kyung Ryu , Sukmook Lee
IPC分类号： G01N33/53 , C12N15/87 , C12P21/06 , C07K16/00 , C07K16/28
CPC分类号： C07K16/2836 , C07K2317/55 , C07K2319/30
摘要： The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells. Accordingly, the monoclonal antibody of the present invention can inhibit a VCAM-1 mediated adhesion of leukocytes to endothelial cells and potently treat VCAM-1 mediated disease, especially inflammatory disease or cancer.
摘要翻译：本发明涉及特异性结合血管细胞粘附分子-1（VCAM-1或CD106）的单克隆抗体。具体地，本发明涉及特异性结合人和小鼠血管细胞粘附分子-1（VCAM-1）的抗体，其制备方法，包含它们的诊断或治疗组合物以及诊断或诊断方法治疗使用它们。本发明的单克隆抗体是人和小鼠VCAM-1特异性的第一种重组单克隆抗体。此外，本发明的单克隆抗体显示出对大鼠骨骼肌和猪内皮细胞以及人和小鼠内皮细胞中表达的VCAM-1的强亲和力，并且发现其强烈抑制白细胞和活化的内皮细胞之间的相互作用。因此，本发明的单克隆抗体可以抑制VCAM-1介导的白细胞对内皮细胞的粘附，并且有效治疗VCAM-1介导的疾病，特别是炎性疾病或癌症。

6. 发明申请

US20090023894A1 Neutralizing Antibody Against HGF 审中-公开
标题翻译： HGF中和抗体
公开(公告)号：US20090023894A1
公开(公告)日：2009-01-22
申请号：US12145643
申请日：2008-06-25
申请人： Junho Chung , Youngmi Hur
发明人： Junho Chung , Youngmi Hur
IPC分类号： C07K7/08
CPC分类号： C07K14/4753 , C07K16/22 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/76
摘要： The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met.
摘要翻译：抗HGF与HGF可发现的可中和表位结合的中和抗体能够作为单一药剂中和HGF，并且可以有效地用于预防和治疗由HGF与其受体Met的结合引起的难治性疾病和癌症。

7. 发明申请

US20070280941A1 VCAM-1 SPECIFIC MONOCLONAL ANTIBODY 失效
标题翻译： VCAM-1特异性单克隆抗体
公开(公告)号：US20070280941A1
公开(公告)日：2007-12-06
申请号：US11756437
申请日：2007-05-31
申请人： Junho Chung , Ji Eun Lee , Eun Kyung Ryu , Sukmook Lee
发明人： Junho Chung , Ji Eun Lee , Eun Kyung Ryu , Sukmook Lee
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2836 , C07K2317/55 , C07K2319/30
摘要： The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells. Accordingly, the monoclonal antibody of the present invention can inhibit a VCAM-1 mediated adhesion of leukocytes to endothelial cells and potently treat VCAM-1 mediated disease, especially inflammatory disease or cancer.
摘要翻译：本发明涉及特异性结合血管细胞粘附分子-1（VCAM-1或CD106）的单克隆抗体。具体地，本发明涉及特异性结合人和小鼠血管细胞粘附分子-1（VCAM-1）的抗体，其制备方法，包含它们的诊断或治疗组合物以及诊断或诊断方法治疗使用它们。本发明的单克隆抗体是对人和小鼠VCAM-1特异的第一种重组单克隆抗体。此外，本发明的单克隆抗体显示出对大鼠骨骼肌和猪内皮细胞以及人和小鼠内皮细胞中表达的VCAM-1的强亲和力，并且发现其强烈抑制白细胞和活化的内皮细胞之间的相互作用。因此，本发明的单克隆抗体可以抑制VCAM-1介导的白细胞对内皮细胞的粘附，并且有效治疗VCAM-1介导的疾病，特别是炎性疾病或癌症。

8. 发明授权

US07718174B2 Anti-HGF/SF humanized antibody 有权
标题翻译：抗HGF / SF人源化抗体
公开(公告)号：US07718174B2
公开(公告)日：2010-05-18
申请号：US11626055
申请日：2007-01-23
申请人： Junho Chung , Kisu Kim
发明人： Junho Chung , Kisu Kim
IPC分类号： A61K39/395 , C12P21/08
CPC分类号： C07K16/32 , A61K39/39558 , A61K2039/505 , C07K2317/24 , A61K2300/00
摘要： The inventive anti-HGF/SF humanized antibody prepared by displaying on the surface of a phage an anti-HGF/SF chimeric Fab library comprising a set of human antibody light chain variable region (VL) and human antibody heavy chain variable region (VH) which are grafted with heavy chain complementary determining regions (HCDRs) of an anti-HGF/SF antibody of an animal other than human, has the equal or greater binding affinity than that of the parent anti-HGF/SF antibody, the neutralizing activity inhibiting the binding of HGF/SF to its receptor, cMET while having the reduced immunogenicity in human. Therefore, the inventive anti-HGF/SF humanized antibody can be used for preventing and treating diseases effectively, e.g., cancers, by the action of binding HGF/SF to cMET.
摘要翻译：通过在噬菌体表面上显示包含一组人抗体轻链可变区（VL）和人抗体重链可变区（VH）的抗HGF / SF嵌合Fab文库制备的本发明抗HGF / SF人源化抗体，其与除人以外的动物的抗HGF / SF抗体的重链互补决定区（HCDR）接枝，具有与母体抗HGF / SF抗体相同或更大的结合亲和力，抑制中和活性 HGF / SF与其受体的结合，cMET在人体中具有降低的免疫原性。因此，通过将HGF / SF结合到cMET的作用，本发明的抗HGF / SF人源化抗体可用于有效地预防和治疗疾病，例如癌症。

9. 发明申请

US20090233358A1 Method of Regulating A Phosphorylated Protein-Mediated Intracellular Signal Transduction Using An Antibody Specifically Binding To The Phosphorylated Protein 审中-公开
标题翻译：使用特异性结合磷酸化蛋白质的抗体调节磷酸化蛋白质介导的细胞内信号转导的方法
公开(公告)号：US20090233358A1
公开(公告)日：2009-09-17
申请号：US12393258
申请日：2009-02-26
申请人： Sue Goo Rhee , Jong Seo Lee , Junho Chung , Hyunbo Shim , Bong Kook Ko , Mi Young Koo
发明人： Sue Goo Rhee , Jong Seo Lee , Junho Chung , Hyunbo Shim , Bong Kook Ko , Mi Young Koo
IPC分类号： C12N5/02 , C07H21/04
CPC分类号： C07K16/18 , C07K16/30 , C07K16/44 , C07K2317/52 , C07K2317/622 , C07K2317/80 , C07K2319/00
摘要： There are provided a method of regulating a phosphorylated protein-mediated intracellular signal transduction comprising intracellularly expressing an antibody that specifically binds to the phosphorylated protein and an expression system for intracellular expression of the antibody. The method and system are effectively used in the investigation, prevention, or treatment of diseases caused by a phosphorylated protein-mediated intracellular signal transduction, including prostate cancer, lung cancer and breast cancer, through regulation of a molecular interaction involving a phosphorylated residue of the phosphorylated protein.
摘要翻译：提供了调节磷酸化蛋白质介导的细胞内信号转导的方法，其包括细胞内表达特异性结合磷酸化蛋白的抗体和用于细胞内表达抗体的表达系统。该方法和系统有效地用于调查，预防或治疗由磷酸化蛋白质介导的细胞内信号转导引起的疾病，包括前列腺癌，肺癌和乳腺癌，通过调节涉及磷酸化残基的分子相互作用磷酸化蛋白。

10. 发明授权

US08586033B2 Integrin αIIbβ3 specific antibodies and peptides 失效
标题翻译：整合素αIIbbeta3特异性抗体和肽
公开(公告)号：US08586033B2
公开(公告)日：2013-11-19
申请号：US10581431
申请日：2004-12-03
申请人： Carlos F. Barbas , Junho Chung
发明人： Carlos F. Barbas , Junho Chung
IPC分类号： A61K39/395 , C07K16/46 , C07K16/28
CPC分类号： C07K16/2848 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention provides integrin αIIbβ3 specific antibodies and peptides. The antibodies and peptides demonstrate little or no immunoreactivity with other integrins. Methods for inhibiting platelet aggregation using the antibodies and peptides are also provided.
摘要翻译：本发明提供整合素αIIbβ3特异性抗体和肽。抗体和肽与其他整合素表现出很少或没有免疫反应性。还提供了使用抗体和肽抑制血小板聚集的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式